Sponsored by:

Syngene

ASSOCIAÇÃO DE TURISMO DO PORTO E NORTE

bioTECH PHARMASUMMIT



21 - 22 March 2019 | Porto

3rd Annual

# BIOSIMILARS AND BIOLOGICS

# DESCRIPTION

On 21 & 22 March 2019, Porto will host the 3rd BioTech Pharma Summit: Biosimilars & Biologics 2019. This year's flagship event will gather top EU, US, Asia and global regulators, officials, healthcare actors as well as industry leaders, to foster open exchange and debate on the role of the biosimilars & biologics medicines sector.

The BioTech Pharma Summit: Biosimilars & Biologics 2019 is the leading event to continually stay on the pulse of the biosimilars' ever-changing market and convenes key stakeholders including biosimilar and innovator pharmaceutical manufacturers, payers, providers and patient advocates addressing timely challenges and best practices for biosimilar product success.


# KEY LEARNING POINTS

- Interchangeability strategy in Biosimilar clinical trial
- Innovations in Biologics Drugs, Biosimilars and Biobetters
- Educational Materials on Biosimilars
- Biosimilar development in emerging markets
- CMC Analytical Comparability: Methods & Strategies for Biologics, Biosimilars & Biobetters
- Prognosis for the Global Biologics market in an era of transformative new technologies
- Critical Analytical Characterization Steps for Biosimilarity Assessment
- Process Development for Biosimilars - Industry challenges
- Biosimilars development and impact on clinical practice
- Pricing and reimbursement considerations for Biosimilars
- Commercial challenges and opportunities - strategies to develop Biosimilars & Biologics
- Relationship between originators' patents in the field of biologics
- Understanding the current regulatory approval standards

# WHO SHOULD ATTEND

The **BioTech Pharma Summit (EPM Group)** are exclusive events designed for senior level attendees from leading **Pharmaceutical, Biopharmaceutical, Biotechnology, Diagnostics, CRO** and Solution Provider companies, along with highly esteemed members of academic and government institutions.

**Chief Executives, Executive Directors, Vice Presidents, Heads and Team Leaders and Managers including:**

- Biologics/Biotechnology/Biogenerics
- Biopharmaceuticals
- Business Development
- Chief Scientific Officer
- Clinical Immunology
- Commercial Affairs
- Drug and Safety Assessment
- Drug Safety & Risk Management
- Intellectual property
- Legislation and Policy Advice
- Manufacturing Market
- Strategy Marketing & sales
- New Product Development
- Pharmacovigilance
- Preclinical and Clinical Development
- Pricing and Reimbursement
- Health Economics
- Principal Scientist
- Process Control and Analytical
- Technologies
- Quality Affairs/Quality Control
- Regulatory Affairs
- Regulatory Compliance
- Legal Affairs
- R&D

# SPEAKERS LIST

**BRENDA GOMES VALENTE**

Health Surveillance and Regulation Specialist at ANVISA

BR

**EMILE VAN CORVEN**

Chief Development Officer at Bioceros

NL

**JUSTIN STEBBING**

Professor of Cancer Medicine and Oncology at Imperial College London

UK

**FERNANDA ALEIXO**

Director Policy & Market Access at Mylan

PT

**NED POJSKIC**

Leader, Pharmacy & Health Provider Relations at Green Shield Canada

CA

**SUZETTE KOX**

Secretary General IGBA (International Generic and Biosimilar medicines Association)

BE

**NIKOLAI BRUN**

Chief Medical Officer. Director of Division at Danish Medicines Agency

DK

**CATE LOCKHART**

Program Director at Biologics and Biosimilars Collective Intelligence Consortium

US

**JOÃO GONÇALVES**

Group Leader/ Principal Investigator at iMed-The Research Institute for Medicines

PT

**RODEINA CHALLAND**

Director at Challand Biosimilar Consulting

Chairperson - DAY 2

UK

**BARBARA VALENTA-SINGER**

Chief Medical Officer at Fresenius-Kabi SwissBioSim

CH

**JOSÉ MARONA**

Resident of Rheumatology Centro Hospitalar de Lisboa Ocidental, EPE - Egas Moniz Hospital

PT

**ROMAN IVANOV**

Vice President, Research & Development at BIOCAD

RU

**LORRAINE FINCHAM**

Commercial Research Initiative Manager at NIHR National Institute for Health Research

UK

**FRANCOIS-XAVIER FRAPAISE**

Principal at F.-X. Frapaise Consulting

FR

**STEINAR MADSEN**

Medical Director at Norwegian Medicines Agency

NO

**ANNA ROSE WELCH**

Chief editor at Biosimilar Development

Chairperson - DAY 1

US

**RAHUL PADHYE**

Vice President and Head, Business Development & Licensing at Cipla Limited

IN

**GILLIAN WOOLLETT**

Senior Vice President at Avalere Health

US

# SCIENTIFIC AGENDA

## Thursday, March 21, 2019 — DAY 1

**08:30** Registration and Welcome Coffee

**09:10** Opening of the BioTech Pharma Summit with the President of INFARMED, Maria do Céu Machado

### THE FUTURE OF BIOSIMILARS

**09:20** Biosimilar global development: after >10years are we closer ?
*By **Barbara Valenta-Singer** - Chief Medical Officer Biosimilar at Fresenius-Kabi SwissBioSim*

- FDA - EMA: how to explain and address different expectations for Equivalence margin, Confidence Interval, clinical endpoints, Reference products
- Why has interchangeability still not taken up?
- How does the practice of settlement interfere with the proposed benefits in case of interchangeability?

**10:00** Speed Networking

**10:20** Advancing Biosimilars in MENA/GCC
*By **Rodeina Challand** - Director at Challand Biosimilar Consulting Ltd*

- Biologic/ Biosimilar uptake
- Regulatory status
- Challenges
- Opportunities

**11:00** Morning Coffee & Networking Break

### REGULATORY LANDSCAPE & PATENT PROTECTION

**11:30** Danish experience with switching treatments for patients on to Biosimilar products – regulatory initiatives
*By **Nikolai Brun** - Chief Medical Officer. Director of Division at Danish Medicines Agency*

- Denmark has championed the active switching of patients onto Biosimilar medicines
- This review will address the experience in Denmark, and the potential pitfalls and benefits of forcing a hard switch regimen through a population

**12:10** **Panel Discussion: Progress in the regulatory landscape for biosimilars**
*Moderated by **Suzette Kox** - Secretary General at IGBA (International Generic and Biosimilar medicines Association)*

*Panelists: **Maria do Céu Machado** - at INFARMED | **Brenda Gomes Valente** - at ANVISA | **Nikolai Brun** - at EMA/DKMA | **Gillian Woollett** - at Avalere Health*

**13:00** Business Lunch

### CLINICAL TRIALS AND REAL-WORLD EVIDENCE

**14:00** Enabling an NHS research-ready workforce to embrace the biosimilars boom
*By **Lorraine Fincham** - Commercial Research Initiative Manager, NIHR*

- Learn how the UK analysed, identified and addressed challenges of embracing the biosimilar boom in the NHS
- Hear UK experiences of creating an educational resource for the research-ready workforce
- Understand how a network approach was a crucial component of the solutions proposed

**14:40** Global Comparator Product for Biosimilar Development and Waiving of Bridging Studies
*By **Suzette Kox** - Secretary General IGBA (International Generic and Biosimilar medicines Association)*

- Definitions of reference, comparator and global comparator product
- Criteria to qualify as comparator product
- Rationale for the global comparator product approach
- Circumstances where bridging studies between local and foreign reference can be waived

**15:20** TBA
*By **Gillian Woollett** - Senior Vice President at Avalere Health*

**16:00** Coffee & Networking Break

**17:00** Clinical studies of mAb biosimilars: are there any regional differences in requirements?
*By **Roman Ivanov** - Vice President, Research & Development at BIOCAD*

- EMA vs. FDA requirements
- Clinical study design issues in China, Russia, India and Latin America
- Requirements for local clinical studies

**17:40** Chairman's Closing Remarks

**19:00** Cocktail Reception

## Friday, March 22, 2019 — DAY 2

08:00 Registration and Welcome Coffee

08:20 Opening Address from the Chaiperson

### BIOSIMILAR CLINICAL DEVELOPMENT: SCIENTIFIC CONSIDERATIONS AND NEW METHODOLOGIES

08:30 **Immunogenicity: anticipating and avoiding issues for biosimilar development**
*By **João Gonçalves** - Group Leader/Principal Investigator at Research Institute for Medicines /Instituto de Investigação do Medicamento (iMed.ULisboa)*

09:10 **Clinical Evidence of Trastuzumab Biosimilar**
*By **Justin Stebbing** - Professor of Cancer Medicine and Oncology at Imperial College London*

09:50 **Switching to biosimilars: What have we learned?**
*Experience of Portuguese rheumatology centers in switching from biooriginators to biosimilars*
*By **José Marona** - Resident of Rheumatology at Centro Hospitalar de Lisboa Ocidental, EPE – Hospital de Egas Moniz*

- General principles of risk management
- Risk management plan (RMP): GVP guidelines
- EU and US approach: RMP vis-à-vis REMS

10:30 Morning Coffee & Networking Break

11:00 **Biosimilars: patient perspectives, challenges and emerging solutions**
*By **Francois-Xavier Frapaise** - Principal at F.-X. Frapaise Consulting*

### BIOSIMILARS | ACCESS & REIMBURSEMENT

11:40 **Biosimilar Transition – A Canadian Insurer's Experience and Perspective**
*By **Ned Pojskic** - Leader, Pharmacy & Health Provider Relations at Green Shield Canada (GSC)*

- This session will explore the evidence supporting biosimilar transitioning and will present one Canadian insurer's experience with a biosimilar transitioning program for patients on Remicade and Enbrel. The results of the program will be presented, with a particular focus on strategies to ensure optimum patient experience, uninterrupted access to safe and effective therapy while providing an important pathway for future sustainability of drug plans

12:20 **Portugal, a case of success of pioneer measures that can inspire other countries**
*By **Fernanda Aleixo** - Director Policy & Market Access at Mylan*

- Reimbursement procedure
- Access: tenders, prescription, selection of medicine, traceability
- Access: more patients treated, at earlier stage of the disease

13:00 Business Lunch

### BIOSIMILARS MANUFACTURING & COMMERCIALIZATION

14:00 **The state of US biosimilar utilization and post-marketing surveillance initiatives to support treatment and coverage decisions**
*By **Cate Lockhart** - Program Director at Biologics and Biosimilars Collective Intelligence Consortium*

- Describe the background of generic drug uptake in the United States and how it relates to the current biosimilar market landscape
- Discuss some of the barriers to market access and utilization of biosimilars in the US: Regulatory questions; Commercial tactics; Stakeholder uncertainty
- Explain the limitations of clinical trial data in supporting clinical and formulary decisions
- Describe one approach to addressing the lack of real-world data and how it could be used for treatment and coverage decision

14:40 **Solve the technical challenges in developing biosimilar antibodies**
*By **Emile van Corven** - Chief Development Officer at Bioceros*

- High titer processes
- Modulation of quality attributes
- Decrease in COGs
- High throughput analytical methods

15:20 **Commercializing Biosimilars in Emerging Markets**
*By **Rahul Padhye** - Head of Business Development and Licensing at Cipla*

- Market size/opportunity
- Regulatory considerations
- Business models
- Key success factors

16:00 Chairman's Closing Remarks and End of Summit

# SPEAKERS BIOGRAPHIES

**SUZETTE KOX, BE**
Secretary General
at IGBA (International
Generic and Biosimilar
medicines Association)

Suzette Kox was nominated Senior Director International in October 2015, following 14 years in the position of EGA's Senior Director Scientific Affairs and Coordinator of the European Biosimilars Group (EBG), now Biosimilar Medicines Group, a sector group of Medicines for Europe (formerly EGA). She was the first Chairperson of the Biosimilars Committee of the International Generic and Biosimilar Medicines Association (IGBA).

**JOSÉ MARONA, PT**
Resident of Rheumatology
Centro Hospitalar de
Lisboa Ocidental, EPE –
Egas Moniz Hospital

José Marona) initiated Rheumatology residentship in 2016 at Hospital Egas Moniz - CHLO (Lisbon, Portugal). Since 2017 he is also a volunteer lecturer of Rheumatology in NOVA Medical School (Lisbon, Portugal) and a collaborator at the Center of Chronic Diseases from NOVA Medical School (CEDOC-NMS). He has participated in several clinical trials and research projects with particular focus on the impact of Biossimilars in the Portuguese market.

**RODEINA CHALLAND, UK**
Director at Challand Biosimilar
Consulting

Rodeina Challand B.Sc., Director, Challand Biosimilar Consulting Ltd., Graduate from London University with over 25 years of experience in healthcare, cancer research and pharmaceutical industry across a wide range of roles including developing and implementing clinical development strategies for biosimilars at Hospira Inc. as Director of Clinical Projects and Head of Clinical Operations in the EU.

**BRENDA GOMES VALENTE, BR**
Health Surveillance and
Regulation Specialist
at ANVISA

Brenda Valente is a Pharmacist, Master in Microbiology by the Federal University of Minas Gerais and Specialist in Pharmaceutical Technology and Health Surveillance. Currently holds the position of Health Surveillance and Regulation Specialist of the Brazilian National Health Regulatory Agency (ANVISA). She works at the Biological's Office at Anvisa since 2005 and her activities includes collaboration in the elaboration of Brazilian regulatory norms and guides on biological products.

**EMILE VAN CORVEN, NL**
Chief Development Officer
at Bioceros

Dr. Emile van Corven is Chief Development Officer at Bioceros. He has a track record of more than 27 years in the biopharmaceutical industry: global head of process development and pilot plant GMP manufacturing of MAbs and vaccines (Crucell/J&J), and the development or recombinant proteins (Pharming). He was also head of the regulatory authority control lab for the release of blood products/vaccines, and head of the regulatory group for review of biotech CMC dossiers.

**NED POJSKIC, CA**
Leader, Pharmacy
& Health Provider Relations at
Green Shield Canada

Ned Pojskic is Green Shield Canada's Leader for Pharmacy and Health Provider Relations. In this role, he is responsible for setting GSC's strategic direction with respect to provider and drug benefits management. He takes the lead in managing stakeholder relations with all health care providers, including pharmacy, dental, and paramedical. Ned is also responsible for overall drug formulary management, including pricing and policy as well as pharmaceutical industry partnerships.

**RAHUL PADHYE, IN**
Vice President and Head,
Business Development &
Licensing at Cipla Limited

Rahul Padhye has been working with Cipla since 2016 as Head BD& Licensing and recently he was assumed responsibility as Global Corporate Development Head. Prior to this, he worked in Reliance Group for 20+ years in various business divisions such as petroleum marketing, infrastructure, alternative energy and life sciences. In life sciences business, he was part of the Executive Management team and was responsible for heading global pharmaceuticals and biosimilars business divisions.

**GILLIAN WOOLLETT, US**
Senior Vice President
at Avalere Health

Gillian Woollett, Senior Vice President, leads our FDA Practice. She provides the "prequel" of scientific and regulatory strategic policy expertise that supports medicinal products gaining approval at the FDA in a manner that allows them to be successful in the public and private reimbursement world. She is building a bridge for Avalere clients from the FDA space into the traditionally separate Centers for Medicare & Medicaid Services and healthcare policy/business world.

**LORRAINE FINCHAM, UK**
Commercial Research
Initiative Manager at NIHR
National Institute for Health
Research

Lorraine Fincham is the Commercial Research Initiative Manager for the NIHR Clinical Research Network (CRN). Lorraine has worked actively as an academic researcher for several London Universities, working on prostate and bowel cancer studies after finishing her degree in Psychology and MSc in Health Psychology. She moved to the NIHR Clinical Research Network in 2007, firstly working locally in the North West London Diabetes Research Network as a Primary Care specialist before moving to the NIHR CRN Coordinating Centre in 2010.

**STEINAR MADSEN, NO**
Medical Director at
Norwegian Medicines Agency

Dr. Steinar Madsen is medical director at the Norwegian Medicines Agency. He has been working with generic substitution since it was introduced in Norway in 2001 and with biosimilars since 2006. He is member and previously chairman of the committee for generic substitution at the Agency. Dr. Madsen is also engaged in the drug information service, with a special interest in the safe and cost-effective use of drugs. He is a specialist in internal medicine and cardiology and works part time as a consultant in cardiology.

**ROMAN IVANOV, RU**
Vice President, Research
& Development at BIOCAD

Dr. Ivanov was in charge of clinical development and registration of the first biosimilar monoclonal antibody approved in Russia – Acellbia (rituximab). He was also in charge of developing the first Russian biosimilar granulocyte colony stimulating factor, the first biosimilar trastuzumab and bevacizumab approved in Russia. Two next-in-class pegylated biologics developed under his supervision have been launched in Russia. Currently he supervises clinical development of several other biosimilars and next-in-class biologics as well as non-clinical studies of multiple innovative products developed by BIOCAD.

**NIKOLAI BRUN, DK**
Chief Medical Officer.
Director of Division at
Danish Medicines Agency

Dr. Nikolai Brun practiced as a physician in the clinical field (Pediatrics) for a couple of years before continuing research and development work in the pharmaceutical industry especially working with biopharmaceuticals. Dr Brun has authored a long list of publications in high-impact journals. Recently he joined the Danish Medicines Agency and has now worked 2 years as Chief Medical Officer and Director of the Division for Medical Evaluation and Biostatistics. Dr Brun is the Chair of the European Medicines Agency (EMA) /Heads of Medicines Agencies (HMA) Big Data Task Force as of April 2018.

## CATE LOCKHART, US

Program Director
at Biologics and Biosimilars Collective Intelligence Consortium

Cate Lockhart, MS, PharmD, PhD is the Program Director for the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC.org) where she is responsible for both the business and research programs of this large, multi-stakeholder research collaboration. She has done extensive research, medical writing and consulting in multiple disease states and therapeutic areas, producing clinical and economic reviews, pharmacoeconomic models and AMCP dossiers to support formulary decisions and value assessments of pharmaceutical products across a variety of therapeutic areas.

## JOÃO GONÇALVES, PT

Group Leader/Principal Investigator at iMed-The Research Institute for Medicines

João Gonçalves is Head of the Biopharmaceutical Biotechnology Unit at the Institute of Innovative Medicines and Professor of Immunology and Biotechnology both part of the Faculty of Pharmacy, University of Lisbon, Portugal. He is also Head of Antibody Engineering Laboratory at iMed – Faculdade Farmacia Universidade Lisboa. Professor João Gonçalves has a pharmaceutical degree and PhD in Immunology at the University of Lisbon, and has obtained Pharmaceutical Medicine management post-graduation from the University of California at San Diego and Post-doctoral training at Scripps Research Institute at La Jolla.

## ANNA ROSE WELCH, US

Chief editor
at Biosimilar Development

Anna Rose Welch is the chief editor of Biosimilar Development, an online publication featuring executive interviews and thought leadership columns about biosimilar industry trends and regulatory/ commercialization challenges. In addition to being a speaker at several U.S. biosimilar conferences, she was also invited to Brazil in 2018 to address members of the Brazilian Ministry of Health, ANVISA, and local biologics and biosimilars manufacturers about how to establish a national biosimilar policy. Her writing will be featured in a book on biosimilars forthcoming from Spinger.

## FRANCOIS-XAVIER FRAPAISE, FR

Principal at F.-X. Frapaise Consulting

Dr. Francois-Xavier Frapaise, M.D has over 35 years of international drug development, strategic planning and marketing experience at major pharmaceutical companies including Sanofi, Bayer, Boehringer, Merck and Abbott; he has hold multiple C-level positions (CSO,CMO,CEO) in different Pharmacos in the US and Europe. Until recently ,he was heading Clinical Development, Medical Affairs and Pharmacovigilance at Merck KGaA Biosimilars Division; he has extensive experience of biosimilars development acquired at Boehringer-Ingelheim and Pfenex); he now runs a consulting business, based in Paris.

## FERNANDA ALEIXO, PT

Director Policy & Market Access at Mylan

Fernanda Aleixo is specialist in Regulatory Affairs and member of the council of specialists of the National Association of Pharmacists. Involved in the launch of first biosimilars medicines in Portugal; Epoetin (2008), Filgrastim (2010) and Infliximab (2013). Leader of the Technical Commission of Apogen (the trade association for generic and biosimilars medicines) from 2012-2015, and from 2016 until now. Developed several activities with different stakeholders aiming to increase the education of the science behind the biosimilars medicines with the goal to share their value for the society, to increase the confidence on these health technologies, and to contribute for more rational and conscientious decisions.

## MARIA DO CÉU MACHADO, PT

President at the National Authority of Medicines and Health Products (INFARMED)

Maria do Céu Machado is a medical doctor (MD, PhD), President of the Executive Board of INFARMED (Portuguese Medicines Agency), Full Professor of Pediatrics at the Faculty of Medicine – Lisbon University, Vice-President of the Federation of European Academies of Medicine and Member of the National Council of Ethics for the Life Sciences. She is an Expert Consultant of the Portuguese Health Plan 2016 – 2020. Prof Machado was High Commissioner for Health (2006-2011) in Portugal, Director of the Department of Pediatrics and Clinical Director of the University Hospital Santa Maria in Lisbon, President of the Nacional Committee for the Children and Adolescents Health and President of the Pediatrics Medical Association.

## BARBARA VALENTA-SINGER, CH

Chief Medical Officer
at Fresenius-Kabi SwissBioSim

Barbara, a MD and pharmacologist by training, has over 25year industry experience gained at Pharmacia, Pfizer, Whyet , Baxter and Baxalta in different medical, clinical, safety and regulatory roles working in local, regional and global organizations. She holds the position of the Chief Medical Officer of the Fresenius Kabi Biosimilar unit. Before joining industry, she had the opportunity to experience the perspective of a Regulatory Agency, Academia and direct patient interactions. Her deep understanding of drug development results from filling operational and strategic assignments with exposure to small molecules and biologics, innovative compounds and Biosimilar. The increasing demand for affordable treatments has attracted her to focus on the challenges of Biosimilar development.

## JUSTIN STEBBING, UK

Professor of Cancer Medicine and Oncology at Imperial College London

Prof Stebbing undertook training and a residency programme at The Johns Hopkins Hospital in the US, returning to London to continue his career in oncology. Prof Stebbing's original PhD research investigated the interplay between the immune system and cancer; he was appointed a senior lecturer in 2007, and a Prof in 2009. Prof Stebbing has published over 600 peer-reviewed papers. The National Institute for Health Research (NIHR) awarded Stebbing its first translational research professorship in oncology, aiming to bridge the gap between the laboratory and the patient to ensure therapy is personalised. In 2016 Justin was internationally recognised with his appointment as Editor-in-Chief of Oncogene (Springer Nature's foremost cancer journal) and election to the American Society for Clinical Investigation.

# REGISTRATION FORM

**PACKAGE NAME**

| | |
|---|---|
| Title: | Title: |
| Name: | Name: |
| Position: | Position: |
| E-mail: | E-mail: |

| | |
|---|---|
| Company: | Postcode: |
| Address: | Phone: |
| City: | Workshop: Yes ☐ No |
| VAT No: | Gala Dinner: Yes ☐ No |
| Signature: | Date: - - |
| | dd mm yyyy |

*This booking is invalid without signature*


**Diogo Lino Ribeiro**
Project Director, Europe | Porto Office

**EM:** diogo.ribeiro@epmgroup.org
**PH:** +351 915 239 640

**Porto Palácio Congress Hotel & Spa*****
Av. da Boavista 1269, 4100-130 Porto


**Please send the signed form to this contact.*

### ACADEMIC/ MED./ NPO PACKAGE
*Individual or Group Registration*

| | |
|---|---|
| 2 days Summit | ✓ |
| Full-Access to All Sessions | ✓ |
| Coffee Breaks/Lunches | ✓ |
| Gala Dinner (Extra 50€) | × |
| Unique 1-on-1 meetings | × |
| Airport Pick-Up/Drop-Off | × |
| Accommodation at the Hotel Venue | × |
| Pre Conference Workshop (Extra 300€) | × |

BOOK NOW

### INDUSTRY BASIC PACKAGE
*Individual Registration*

| | |
|---|---|
| 2 days Summit | ✓ |
| Full-Access to All Sessions | ✓ |
| Coffee Breaks/Lunches | ✓ |
| Gala Dinner | ✓ |
| Unique 1-on-1 meetings | ✓ |
| Airport Pick-Up/Drop-Off | × |
| Accommodation at the Hotel Venue | × |
| Pre Conference Workshop (Extra 300€) | × |

BOOK NOW

### INDUSTRY PREMIUM PACKAGE
*Individual Registration*

| | |
|---|---|
| 2 days Summit | ✓ |
| Full-Access to All Sessions | ✓ |
| Coffee Breaks/Lunches | ✓ |
| Gala Dinner | ✓ |
| Unique 1-on-1 meetings | ✓ |
| Airport Pick-Up/Drop-Off | ✓ |
| Accommodation at the Hotel Venue | ✓ |
| Pre Conference Workshop | ✓ |

BOOK NOW

| | *Super Early Bird* **Until December 14** | *Early Bird* **Until February 15** | *Discounted Ticket* **Until March 8** | *Normal Ticket* **After March 8** |
|---|---|---|---|---|
| Academic/ Med./ NPO Package | 500€ | 600€ | 650€ | 850€ |
| Industry Package | 1,495€ | 1,695€ | 1,795€ | 1,995€ |
| Premium Package | 2,800€ | 3,000€ | 3,250€ | 3,550€ |

**The 3rd Annual Biosimilars & Biologics 2019 is an exclusive limited seat event. Early bird tickets are non-refundable and subject to availability.*

| Team Discounts | Until December 14 | Until February 15 | Until March 8 | After March 8 |
|---|---|---|---|---|
| 2 Delegates | 10% | 5% | - | - |
| 3 Delegates | 15% | 10% | 5% | - |
| 4+ Delegates | 20% | 15% | 10% | 5% |

All Prices displayed include VAT @ The VAT amount will be displayed after the payment process and shown on your invoice.

# SPONSORSHIP PACKAGES

**Assembly of your space and the design of your booth will be supported by us*

### GOLD SPONSORSHIP (VAT INC.) 15,995€

- Opportunity to give a speech at the beginning of the conference [up to 40min]
- 8m2 exhibition space with LCD Monitor for Video Presentations
- Table & Spiderwall with design customized by the client*
- FULL page Ad in conference program
- Company Banner displayed at all the Sessions including Gala Dinner
- Logo on the conference website and main stage
- Flyer/promo gifts into congress bags
- Branding at post-event communication activities
- Access to all Sessions
- Business Lunches & Gala Dinner
- Exclusive One-on-One Meetings
- Up to 5 delegates FREE-Admission (25% discount for extra ticket)
- VIP Airport Pick-up Service
- 2 nights accommodation for 5 delegates registered

### SILVER SPONSORSHIP (VAT INC.) 12,995€

- Speaking slot [up to 40min]
- 6m2 exhibition space with LCD Monitor for Video Presentations
- Table & Spiderwall with design customized by the client*
- ½ page Ad in conference program
- Company Banner displayed at the reception desk & Coffee breaks
- Logo on the conference website and main stage
- Flyer/promo gifts into congress bags
- Branding at post-event communication activities
- Access to all Sessions
- Business Lunches & Gala Dinner
- Exclusive One-on-One Meetings
- Up to 4 delegates FREE-Admission (25% discount for extra ticket)
- VIP Airport Pick-up Service
- 2 nights accommodation for 4 delegates registered

### BRONZE SPONSORSHIP (VAT INC.) 8,995€

- Speaking slot [up to 40min]
- 6m2 exhibition space
- Table & Spiderwall with design customized by the client*
- ¼ page Ad in conference program
- Company Banner displayed at the reception desk
- Logo on the conference website and main stage
- Flyer/promo gifts into congress bags
- Branding at post-event communication activities
- Access to all Sessions
- Business Lunches & Gala Dinner
- Exclusive One-on-One Meetings
- Up to 3 delegates FREE-Admission (25% discount for extra ticket)
- VIP Airport Pick-up Service
- 2 nights accommodation for 3 delegates registered

### SPEAKER SPONSORSHIP (VAT INC.) 5,995€

- Speaking slot [up to 40min]
- 3m2 exhibition space
- Table & Spiderwall with design customized by the client*
- Logo on the conference website and main stage
- Flyer/promo gifts into congress bags
- Branding at post-event communication activities
- Access to all Sessions
- Business Lunches & Gala Dinner
- Exclusive One-on-One Meetings
- Up to 3 delegates FREE-Admission (25% discount for extra ticket)

### KEYNOTE SPEECH PACKAGE (VAT INC.) 3,550€

- Speaking slot [up to 40min]
- Logo on the conference website and main stage
- Flyer/promo gifts into congress bags
- Branding at post-event communication activities
- Access to all Sessions
- Business Lunches & Gala Dinner
- Exclusive One-on-One Meetings
- Up to 2 delegates FREE-Admission (25% discount for extra ticket)

### EXHIBITION PACKAGE (VAT INC.) 3,550€

- 3m2 exhibition space
- Table & Spiderwall with design customized by the client*
- Logo on the conference website and main stage
- Flyer/promo gifts into congress bags
- Branding at post-event communication activities
- Access to all Sessions
- Business Lunches & Gala Dinner
- Exclusive One-on-One Meetings
- Up to 2 delegates FREE-Admission (25% discount for extra ticket)

***Click bellow to register as a sponsor***

**ONLINE REGISTRATION**

By sending this form, I confirm that I have read and accepted the terms and conditions detailed below.

**Confirmation**
We will confirm your participation after receiving the signed registration form the delegate will receive the invoice within 24h of sending the signed form. The hotel details will be sent 2 or 3 weeks before the start of the conference.

**Cancellations**
Cancellations made one month prior to the start of the conference will be refunded less 50% administration charge. Refunds will be made after the conference. Cancellations made within one month of the conference start date will receive no refund. Substitutes are accepted up to 3 days before the conference. Any cancellation will be accepted latest one month before the event and should be informed in written form.

**Force Majeure**
While every reasonable effort will be made to adhere to the advertised package, EPM Group reserves the right to change event dates, sites or location, omit event features, or merge the event with another event as it deems necessary without penalty and in such situations no refunds, part refunds or alternative offers shall be made (including, but not limited to any force majeure occurence) and provided that the event is not postponed to a later date nor is it merged with another event, the client shall receive a credit note for the amount that the client has paid to such permanently canceled event. No refunds, part refunds or alternative offers shall be made.

**Copyright**

biosimilars-summit.com

EPM Group